Jeffrey Heier
Retina Specialist · Boston, MANPI 1578546917
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.4%), ownership interests and speaking fees — rather than concentrated in one kind of arrangement. Ocular Therapeutix, Inc. accounts for 63.5% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $390,891 and has fallen 93.0% since, to $27,505 in 2025. Among retina specialist clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $5622.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$957K
- Novartis$144K
- Novartis Pharma AG$88K
- Regeneron$81K
- Genentech, Inc.$31K
- Apellis Pharmaceuticals, Inc.$31K
- plus $174K from 25 others
Across 676 payments — averaging $20,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$8.9M
- Genentech, Inc.$1.9M
- Regeneron$1.1M
- Apellis Pharmaceuticals, Inc.$994K
- Bayer$796K
- Janssen Research & Development, LLC$237K
- plus $175K from 9 others
What the payments were for
- Royalty or licence$14,4301%
- Consulting fees$563,54937%
- Speaking & faculty fees$312,97921%
- Grants$157,50010%
- Travel & lodging$2,4960%
- Food & beverage$5,1930%
- Ownership interest$450,55830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 47 | $957,147 |
| Novartis | 21 | $144,337 |
| Novartis Pharma AG | 25 | $87,840 |
| Regeneron | 45 | $81,355 |
| Genentech, Inc. | 12 | $31,101 |
| Apellis Pharmaceuticals, Inc. | 18 | $31,043 |
| Janssen Global Services, LLC | 13 | $21,686 |
| Janssen Research & Development, LLC | 19 | $18,825 |
| Sanofi US Services Inc. | 7 | $14,607 |
| AbbVie(2 entities) | 10 | $14,596 |
| Boehringer Ingelheim International GmbH | 5 | $14,531 |
| Astellas Pharma US Inc | 4 | $14,500 |
| Alcon Research LLC | 1 | $14,430 |
| Shire North American Group Inc | 5 | $10,690 |
| Eli Lilly | 5 | $8,000 |
| F. Hoffmann-la Roche AG | 1 | $7,333 |
| Daiichi Sankyo Inc. | 3 | $6,500 |
| Aerie Pharmaceuticals, Inc. | 6 | $6,103 |
| Notal Vision, Inc. | 2 | $5,400 |
| Regeneron Healthcare Solutions, Inc. | 4 | $4,354 |
| Astellas Pharma Global Development | 1 | $3,600 |
| Samsung Bioepis Co., Ltd. | 2 | $2,200 |
| Amgen | 1 | $1,886 |
| Bausch & Lomb Americas Inc. | 3 | $1,663 |
| Harrow Eye, LLC | 2 | $1,400 |
| Thrombogenics, Inc. | 1 | $1,320 |
| Alcon | 1 | $130 |
| Roche Products Limited | 1 | $64 |
| Sanofi-aventis U.S. LLC | 1 | $32 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Optovue, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$167,533
- DEXTENZA$158,480
- EYLEA$83,547
- Lucentis$30,971
- RTH258A_BEOVU_OPHTHALMOLOGY$21,500
- Izervay$18,100
- BVU_BEOVU_OPHTHALMOLOGY$15,588
- NGENUITY$14,430
- BLZ_BEOVU_OPHTHALMOLOGY$9,138
- TAKHZYRO$8,500
- BUPARLISIB$5,497
- ForeseeHome$5,400
- OZURDEX$4,000
- E301$2,200
- BROLUCIZUMAB_BEOVU_OPHTHALMOLOGY$2,150
- EYLEA HD$2,040
- IHEEZO$1,400
- Jetrea$1,320
- Syfovre$706
- TRIESENCE$700
How this compares
$1,506,705 in reported general payments places this provider in the 95th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 31 | $6,562 |
| ProlensaBromfenac Sodium | 16 | $6,317 |
| Difluprednate | 28 | $2,814 |
| Prednisolone Acetate | 56 | $1,804 |
| Brimonidine Tartrate | 38 | $1,196 |
| Atropine Sulfate | 26 | $739 |
| Ketorolac Tromethamine | 16 | $520 |
| Timolol Maleate | 16 | $178 |
| Latanoprost | 13 | $121 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $18 | $6,31716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 retina specialist providers in Massachusetts.
Other retina specialist in Boston
- Andre WitkinBoston$23K
- Chirag ShahBoston$14K
- Brian BalliosBoston$3K
- Ilya LeskovBoston$2K
- Siamak ShokrollahiBoston$806
- Omar AbdelalBoston$806
- Xiang WerdichBoston$686
- Mohamed ElmasryBoston$190
- Tina ClearyBoston$184
- Miriam Englander Paschalis IliosBoston$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.